Zoetis Inc. (ZTS) KPIs and segments
Close on Nov 18, 2026Market cap $35.36BP/E 14.1Yield 2.37%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Zoetis · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026; effective FY2026, international subsidiaries aligned from a November 30 fiscal year-end to December 31)
Nhìn nhanh KPI của Zoetis: 42 chỉ số vận hành, trong đó có Total Consolidated Revenue, U.S. Operating Segment Revenue và International Operating Segment Revenue, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
U.S.($M)2 | 1,266 | 1,090 | 1,236 | 1,322 | 1,356 | 1,183 | 1,257 | 1,346 | 1,308 | 1,163 | 1,211 | ||
Companion animal($M) | 1,044 | 865 | 1,002 | 1,069 | 1,176 | 973 | 1,008 | 1,068 | 1,080 | 898 | 941 | ||
Livestock($M) | 222 | 225 | 234 | 253 | 180 | 210 | 249 | 278 | 228 | 265 | 270 | ||
International($M)2 | 1,173 | 1,149 | 1,121 | 1,055 | 1,085 | 985 | 1,039 | 1,021 | 1,035 | 1,007 | 982 | ||
Companion animal($M) | 664 | 654 | 599 | 583 | 614 | 568 | 562 | 541 | 569 | 552 | 507 | ||
Livestock($M) | 509 | 495 | 522 | 472 | 471 | 417 | 477 | 480 | 466 | 455 | 475 | ||
Companion animal($M) | 1,708 | 1,519 | 1,601 | 1,652 | 1,790 | 1,541 | 1,570 | 1,609 | 1,649 | 1,450 | 1,448 | ||
Dogs and Cats($M) | 1,634 | 1,443 | 1,586 | 1,719 | 1,477 | 1,551 | 1,581 | 1,384 | |||||
Livestock($M) | 731 | 720 | 756 | 725 | 651 | 627 | 726 | 758 | 694 | 720 | 745 | ||
Parasiticides($M) | 698 | 586 | 542 | 564 | 660 | 572 | 519 | 530 | 600 | 504 | 482 | ||
Vaccines($M) | 521 | 519 | 512 | 496 | 510 | 439 | 462 | 468 | 445 | 452 | 463 | ||
Dermatology($M) | 398 | 349 | 429 | 472 | 473 | 379 | 421 | 453 | 418 | 363 | 379 | ||
Cattle($M) | 390 | 392 | 415 | 399 | 323 | 341 | 399 | 391 | 350 | 391 | 401 | ||
Anti-infectives($M) | 244 | 241 | 284 | 284 | 222 | 238 | 281 | 274 | 264 | 281 | 261 | ||
Pain and sedation($M) | 217 | 203 | 209 | 204 | 223 | 207 | 217 | 219 | 221 | 194 | 194 | ||
Other pharmaceutical($M) | 168 | 158 | 188 | 178 | 175 | 158 | 180 | 169 | 153 | 156 | 164 | ||
Animal health diagnostics($M) | 123 | 117 | 111 | 110 | 110 | 104 | 100 | 101 | 103 | 82 | 92 | ||
Swine($M) | 117 | 123 | 125 | 111 | 118 | 105 | 128 | 131 | 130 | 127 | 139 | ||
Poultry($M) | 115 | 118 | 117 | 106 | 104 | 106 | 117 | 139 | 132 | 139 | 127 | ||
Fish($M) | 83 | 66 | 81 | 78 | 81 | 55 | 65 | 70 | 62 | 45 | 62 | ||
Horses($M) | 74 | 76 | 6,080 | 66 | 71 | 64 | 5,801 | 58 | 68 | 66 | 5,094 | ||
Other non-pharmaceutical($M) | 70 | 66 | 70 | 64 | 68 | 71 | 65 | 62 | 65 | 61 | 61 | ||
Contract manufacturing & human health($M) | 29 | 23 | 30 | 23 | 33 | 30 | 21 | 21 | 18 | 20 | |||
Sheep and other($M) | 26 | 21 | 18 | 31 | 25 | 20 | 17 | 27 | 20 | 18 | 16 | ||
Medicated feed additives($M) | 12 | 5 | 5 | 5 | 51 | 91 | 74 | 77 | 97 | ||||
United States($M) | 1,266 | 1,090 | 1,236 | 1,322 | 1,356 | 1,183 | 1,257 | 1,346 | 1,308 | 1,163 | 1,211 | ||
Other emerging markets($M) | 269 | 291 | 212 | 228 | 223 | 238 | 195 | 220 | 222 | 228 | 179 | ||
Other developed markets($M) | 187 | 169 | 182 | 164 | 175 | 133 | 151 | 148 | 138 | 127 | 138 | ||
Brazil($M) | 103 | 90 | 112 | 100 | 93 | 81 | 113 | 101 | 99 | 101 | 117 | ||
Australia($M) | 94 | 89 | 84 | 87 | 83 | 79 | 80 | 83 | 83 | 73 | 75 | ||
Canada($M) | 72 | 73 | 80 | 70 | 71 | 70 | 75 | 66 | 75 | 61 | 72 | ||
United Kingdom($M) | 72 | 78 | 89 | 82 | 81 | 74 | 84 | 80 | 73 | 77 | 68 | ||
Germany($M) | 69 | 59 | 65 | 62 | 57 | 55 | 59 | 57 | 58 | 51 | 54 | ||
China($M) | 62 | 63 | 50 | 45 | 67 | 55 | 65 | 61 | 68 | 76 | 65 | ||
Mexico($M) | 47 | 48 | 44 | 41 | 39 | 35 | 40 | 39 | 46 | 44 | 43 | ||
Spain($M) | 43 | 40 | 37 | 38 | 40 | 29 | 30 | 35 | 33 | 32 | 28 | ||
Japan($M) | 41 | 35 | 39 | 34 | 43 | 32 | 38 | 33 | 39 | 37 | 38 | ||
France($M) | 40 | 37 | 52 | 40 | 42 | 39 | 45 | 36 | 34 | 41 | 40 | ||
Italy($M) | 40 | 39 | 35 | 35 | 37 | 30 | 34 | 31 | 36 | 28 | 34 | ||
Chile($M) | 34 | 38 | 40 | 29 | 34 | 35 | 30 | 31 | 31 | 31 | 31 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
U.S.($M) | 1,052 | 896 | 1,023 | 1,100 | 1,148 | 984 | 1,028 | 1,088 | 1,076 | 946 | 956 | ||
International($M) | 833 | 815 | 756 | 724 | 764 | 690 | 703 | 700 | 693 | 694 | 660 | ||
U.S.($M) | 837 | 697 | 830 | 899 | 930 | 779 | 819 | 889 | 872 | 756 | 766 | ||
International($M) | 661 | 639 | 574 | 556 | 592 | 527 | 523 | 542 | 518 | 535 | 494 | ||
Other business activities($M) | -141 | -159 | -140 | -134 | -133 | -151 | -137 | -142 | -132 | -142 | |||
Total Consolidated Revenue ($M)($M)8 | 2,391 | 2,468 | 2,262 | 2,387 | 2,400 | 2,460 | 2,220 | 2,317 | 2,388 | 2,361 | 2,190 | 2,213 | |
Total Product & Service Revenue (Reportable Segments: U.S. + International) ($M)($M) | 2,362 | 2,439 | 2,239 | 2,357 | 2,396 | 2,441 | 2,168 | 2,296 | 2,367 | 2,343 | 2,170 | 2,193 | |
Contract Manufacturing & Human Health Revenue ($M)($M)5 | 29 | 29 | 23 | 30 | 23 | 34 | 29 | 21 | 21 | 18 | 20 | 20 | |
Contract Manufacturing & Human Health Revenue — Reported growth YoY (%)(%) | 12.0% | -12.0% | -23.0% | 43.0% | 10.0% | 89.0% | 45.0% | 5.0% | 0.0% | -10.0% | 18.0% | -26.0% | |
Contract Manufacturing & Human Health Revenue — Foreign exchange impact YoY (%)(%) | -3.0% | 1.0% | 1.0% | 6.0% | 0.0% | -2.0% | -6.0% | 0.0% | -2.0% | -1.0% | 2.0% | 1.0% | |
Contract Manufacturing & Human Health Revenue — Operational (constant-currency) growth YoY (%)(%) | 15.0% | -13.0% | -24.0% | 37.0% | 10.0% | 91.0% | 51.0% | 5.0% | 2.0% | -9.0% | 16.0% | -27.0% | |
Contract Manufacturing & Human Health Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
Contract Manufacturing & Human Health Revenue — Organic operational growth YoY (%)(%) | 15.0% | -13.0% | -24.0% | 37.0% | 10.0% | 91.0% | 51.0% | 5.0% | 2.0% | -9.0% | 16.0% | -27.0% | |
MD&A Operational Revenue Change YoY ($M)($M)6 | -44 | -41 | -12 | 206 | 216 | 103 | 297 | 243 | 239 | ||||
MD&A Reported Revenue Change YoY ($M)($M) | -31 | -6 | 64 | 141 | 129 | 30 | 237 | 181 | 190 | ||||
MD&A Foreign Exchange Impact on Revenue YoY ($M)($M) | 13 | 35 | 76 | ||||||||||
MD&A Revenue Driver — Volume from Key Franchises Contribution (%)(%) | -1.0% | -3.0% | -3.0% | 4.0% | 2.0% | 2.0% | 3.0% | ||||||
MD&A Revenue Driver — Volume from Other In-Line Products Contribution (%)(%) | 1.0% | 2.0% | 1.0% | 1.0% | 3.0% | -2.0% | -2.0% | ||||||
MD&A Revenue Driver — MFA Divestiture Volume Impact (%)(%) | -1.0% | -1.0% | -1.0% | -4.0% | |||||||||
MD&A Revenue Driver — Volume from New Products [legacy through FY24] (%)(%) | 3.0% | 3.0% | 4.0% | ||||||||||
Total Consolidated Revenue — Reported growth YoY (%)(%) | -1.0% | 0.0% | 3.0% | 3.0% | 1.0% | 4.0% | 1.0% | 5.0% | 11.0% | 8.0% | 10.0% | 8.0% | |
Total Consolidated Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 2.0% | 4.0% | 1.0% | 1.0% | -1.0% | -4.0% | -1.0% | -3.0% | -3.0% | -2.0% | 0.0% | |
Total Consolidated Revenue — Operational (constant-currency) growth YoY (%)(%) | -2.0% | -2.0% | -1.0% | 2.0% | 0.0% | 5.0% | 5.0% | 6.0% | 14.0% | 11.0% | 12.0% | 8.0% | |
Total Consolidated Revenue — Divestitures impact YoY (%)(%) | -1.0% | -1.0% | -1.0% | -2.0% | -4.0% | -3.0% | -4.0% | ||||||
Total Consolidated Revenue — Organic operational growth YoY (%)(%) | -1.0% | -1.0% | 0.0% | 4.0% | 4.0% | 8.0% | 9.0% | 6.0% | 14.0% | 11.0% | 12.0% | 8.0% | |
U.S. Operating Segment Revenue ($M)($M)7 | 1,246 | 1,266 | 1,090 | 1,236 | 1,322 | 1,356 | 1,183 | 1,257 | 1,346 | 1,308 | 1,163 | 1,211 | |
U.S. Companion Animal Revenue ($M)($M)5 | 980 | 1,044 | 865 | 1,002 | 1,069 | 1,176 | 973 | 1,008 | 1,068 | 1,080 | 898 | 941 | |
U.S. Companion Animal Revenue — Reported growth YoY (%)(%) | -8.0% | -11.0% | -11.0% | -1.0% | 0.0% | 9.0% | 8.0% | 7.0% | 18.0% | 13.0% | 25.0% | 10.0% | |
U.S. Companion Animal Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
U.S. Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%) | -8.0% | -11.0% | -11.0% | -1.0% | 0.0% | 9.0% | 8.0% | 7.0% | 18.0% | 13.0% | 25.0% | 10.0% | |
U.S. Companion Animal Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
U.S. Companion Animal Revenue — Organic operational growth YoY (%)(%) | -8.0% | -11.0% | -11.0% | -1.0% | 0.0% | 9.0% | 8.0% | 7.0% | 18.0% | 13.0% | 25.0% | 10.0% | |
U.S. Livestock Revenue ($M)($M)5 | 266 | 222 | 225 | 234 | 253 | 180 | 210 | 249 | 278 | 228 | 265 | 270 | |
U.S. Livestock Revenue — Reported growth YoY (%)(%) | 5.0% | 23.0% | 7.0% | -6.0% | -9.0% | -21.0% | -21.0% | -8.0% | 5.0% | 11.0% | -7.0% | 4.0% | |
U.S. Livestock Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
U.S. Livestock Revenue — Operational (constant-currency) growth YoY (%)(%) | 5.0% | 23.0% | 7.0% | -6.0% | -9.0% | -21.0% | -21.0% | -8.0% | 5.0% | 11.0% | -7.0% | 4.0% | |
U.S. Livestock Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | -9.0% | -23.0% | -19.0% | -19.0% | ||||||
U.S. Livestock Revenue — Organic operational growth YoY (%)(%) | 5.0% | 23.0% | 7.0% | 3.0% | 14.0% | -2.0% | -2.0% | -8.0% | 5.0% | 11.0% | -7.0% | 4.0% | |
U.S. Operating Segment Revenue — Reported growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | -2.0% | -2.0% | 4.0% | 2.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
U.S. Operating Segment Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
U.S. Operating Segment Revenue — Operational (constant-currency) growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | -2.0% | -2.0% | 4.0% | 2.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
U.S. Operating Segment Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | -2.0% | -5.0% | -3.0% | -4.0% | ||||||
U.S. Operating Segment Revenue — Organic operational growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | 0.0% | 3.0% | 7.0% | 6.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
International Operating Segment Revenue ($M)($M)7 | 1,116 | 1,173 | 1,149 | 1,121 | 1,055 | 1,070 | 1,008 | 1,039 | 1,021 | 1,035 | 1,007 | 982 | |
International Companion Animal Revenue ($M)($M)5 | 585 | 664 | 654 | 599 | 583 | 612 | 573 | 562 | 541 | 569 | 552 | 507 | |
International Companion Animal Revenue — Reported growth YoY (%)(%) | 1.0% | 8.0% | 15.0% | 7.0% | 8.0% | 8.0% | 4.0% | 11.0% | 7.0% | 7.0% | 10.0% | 13.0% | |
International Companion Animal Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 3.0% | 8.0% | 3.0% | 4.0% | 0.0% | -6.0% | -2.0% | -4.0% | -5.0% | -4.0% | 3.0% | |
International Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%) | 0.0% | 5.0% | 7.0% | 4.0% | 4.0% | 8.0% | 10.0% | 13.0% | 11.0% | 12.0% | 14.0% | 10.0% | |
International Companion Animal Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
International Companion Animal Revenue — Organic operational growth YoY (%)(%) | 0.0% | 5.0% | 7.0% | 4.0% | 4.0% | 8.0% | 10.0% | 13.0% | 11.0% | 12.0% | 14.0% | 10.0% | |
International Livestock Revenue ($M)($M)5 | 531 | 509 | 495 | 522 | 472 | 458 | 435 | 477 | 480 | 466 | 455 | 475 | |
International Livestock Revenue — Reported growth YoY (%)(%) | 8.0% | 8.0% | 19.0% | 9.0% | -2.0% | -2.0% | -4.0% | 0.0% | 7.0% | 0.0% | -4.0% | 5.0% | |
International Livestock Revenue — Foreign exchange impact YoY (%)(%) | 2.0% | 4.0% | 7.0% | 2.0% | 1.0% | -3.0% | -8.0% | -6.0% | -8.0% | -8.0% | -6.0% | -2.0% | |
International Livestock Revenue — Operational (constant-currency) growth YoY (%)(%) | 6.0% | 4.0% | 12.0% | 7.0% | -3.0% | 1.0% | 4.0% | 6.0% | 15.0% | 8.0% | 2.0% | 7.0% | |
International Livestock Revenue — Divestitures impact YoY (%)(%) | -3.0% | -2.0% | -2.0% | -5.0% | -11.0% | -9.0% | -8.0% | ||||||
International Livestock Revenue — Organic operational growth YoY (%)(%) | 9.0% | 6.0% | 14.0% | 12.0% | 8.0% | 10.0% | 12.0% | 6.0% | 15.0% | 8.0% | 2.0% | 7.0% | |
International Operating Segment Revenue — Reported growth YoY (%)(%) | 4.0% | 8.0% | 17.0% | 8.0% | 3.0% | 3.0% | 0.0% | 6.0% | 7.0% | 4.0% | 3.0% | 9.0% | |
International Operating Segment Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 3.0% | 8.0% | 3.0% | 2.0% | -2.0% | -7.0% | -4.0% | -6.0% | -6.0% | -5.0% | 1.0% | |
International Operating Segment Revenue — Operational (constant-currency) growth YoY (%)(%) | 3.0% | 5.0% | 9.0% | 5.0% | 1.0% | 5.0% | 7.0% | 10.0% | 13.0% | 10.0% | 8.0% | 8.0% | |
International Operating Segment Revenue — Divestitures impact YoY (%)(%) | -1.0% | -1.0% | -1.0% | -2.0% | -5.0% | -4.0% | -4.0% | ||||||
International Operating Segment Revenue — Organic operational growth YoY (%)(%) | 4.0% | 6.0% | 10.0% | 7.0% | 6.0% | 9.0% | 11.0% | 10.0% | 13.0% | 10.0% | 8.0% | 8.0% | |
Total Companion Animal Revenue ($M)($M)7 | 1,565 | 1,708 | 1,519 | 1,601 | 1,652 | 1,788 | 1,546 | 1,570 | 1,609 | 1,649 | 1,450 | 1,448 | |
Dogs and Cats Revenue ($M)($M)4 | 1,492 | 1,634 | 1,443 | 1,500 | 1,586 | 1,716 | 1,481 | 1,477 | 1,551 | 1,581 | 1,384 | 1,360 | |
Dogs and Cats Revenue — Reported growth YoY (%)(%) | -6.0% | -5.0% | -2.0% | 2.0% | 2.0% | 9.0% | 7.0% | 9.0% | 15.0% | 11.0% | 20.0% | 11.0% | |
Dogs and Cats Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 1.0% | 3.0% | 1.0% | 1.0% | 0.0% | -2.0% | 0.0% | -1.0% | -2.0% | -2.0% | 1.0% | |
Dogs and Cats Revenue — Operational (constant-currency) growth YoY (%)(%) | -6.0% | -6.0% | -5.0% | 1.0% | 1.0% | 9.0% | 9.0% | 9.0% | 16.0% | 13.0% | 22.0% | 10.0% | |
Dogs and Cats Revenue — Organic operational growth YoY (%)(%) | -6.0% | -6.0% | -5.0% | 1.0% | 1.0% | 9.0% | 9.0% | 9.0% | 16.0% | 13.0% | 22.0% | 10.0% | |
Horses (Equine) Revenue ($M)($M)4 | 73 | 74 | 76 | 101 | 66 | 72 | 65 | 93 | 58 | 68 | 66 | 88 | |
Horses (Equine) Revenue — Reported growth YoY (%)(%) | 6.0% | 4.0% | 19.0% | 9.0% | 14.0% | 6.0% | -2.0% | 6.0% | -3.0% | 5.0% | -8.0% | 11.0% | |
Horses (Equine) Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 1.0% | 6.0% | 3.0% | 0.0% | 0.0% | -4.0% | -1.0% | -2.0% | -1.0% | -2.0% | 0.0% | |
Horses (Equine) Revenue — Operational (constant-currency) growth YoY (%)(%) | 6.0% | 3.0% | 13.0% | 6.0% | 14.0% | 6.0% | 2.0% | 7.0% | -1.0% | 6.0% | -6.0% | 11.0% | |
Horses (Equine) Revenue — Organic operational growth YoY (%)(%) | 6.0% | 3.0% | 13.0% | 6.0% | 14.0% | 6.0% | 2.0% | 7.0% | -1.0% | 6.0% | -6.0% | 11.0% | |
Total Companion Animal Revenue — Reported growth YoY (%)(%) | -5.0% | -5.0% | -1.0% | 2.0% | 3.0% | 8.0% | 7.0% | 8.0% | 14.0% | 11.0% | 18.0% | 11.0% | |
Total Companion Animal Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 1.0% | 3.0% | 1.0% | 1.0% | 0.0% | -2.0% | -1.0% | -1.0% | -1.0% | -2.0% | 1.0% | |
Total Companion Animal Revenue — Operational (constant-currency) growth YoY (%)(%) | -5.0% | -6.0% | -4.0% | 1.0% | 2.0% | 8.0% | 9.0% | 9.0% | 15.0% | 12.0% | 20.0% | 10.0% | |
Total Companion Animal Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
Total Companion Animal Revenue — Organic operational growth YoY (%)(%) | -5.0% | -6.0% | -4.0% | 1.0% | 2.0% | 8.0% | 9.0% | 9.0% | 15.0% | 12.0% | 20.0% | 10.0% | |
Total Livestock Revenue ($M)($M)10 | 797 | 731 | 720 | 756 | 725 | 638 | 645 | 726 | 758 | 694 | 720 | 745 | |
Cattle (Beef & Dairy) Revenue ($M)($M)4 | 439 | 390 | 392 | 415 | 399 | 320 | 358 | 399 | 391 | 350 | 391 | 401 | |
Cattle (Beef & Dairy) Revenue — Reported growth YoY (%)(%) | 6.0% | 21.0% | 15.0% | 4.0% | 2.0% | -9.0% | -8.0% | 0.0% | 5.0% | 6.0% | -2.0% | 6.0% | |
Cattle (Beef & Dairy) Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 3.0% | 4.0% | 1.0% | 0.0% | -3.0% | -5.0% | -4.0% | -4.0% | -6.0% | -3.0% | -1.0% | |
Cattle (Beef & Dairy) Revenue — Operational (constant-currency) growth YoY (%)(%) | 5.0% | 18.0% | 11.0% | 3.0% | 2.0% | -6.0% | -3.0% | 4.0% | 9.0% | 12.0% | 1.0% | 7.0% | |
Cattle (Beef & Dairy) Revenue — Organic operational growth YoY (%)(%) | 5.0% | 18.0% | 11.0% | 3.0% | 2.0% | -6.0% | -3.0% | 4.0% | 9.0% | 12.0% | 1.0% | 7.0% | |
Swine Revenue ($M)($M)4 | 120 | 117 | 123 | 125 | 111 | 119 | 111 | 128 | 131 | 130 | 127 | 139 | |
Swine Revenue — Reported growth YoY (%)(%) | 3.0% | -1.0% | 17.0% | -2.0% | -15.0% | -8.0% | -13.0% | -8.0% | 2.0% | -2.0% | -11.0% | 1.0% | |
Swine Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 2.0% | 6.0% | 2.0% | 2.0% | -1.0% | -6.0% | -4.0% | -7.0% | -7.0% | -4.0% | 1.0% | |
Swine Revenue — Operational (constant-currency) growth YoY (%)(%) | 2.0% | -3.0% | 11.0% | -4.0% | -17.0% | -7.0% | -7.0% | -4.0% | 9.0% | 5.0% | -7.0% | 0.0% | |
Swine Revenue — Organic operational growth YoY (%)(%) | 2.0% | -3.0% | 11.0% | -4.0% | -17.0% | -7.0% | -7.0% | -4.0% | 9.0% | 5.0% | -7.0% | 0.0% | |
Poultry Revenue ($M)($M)4 | 108 | 115 | 118 | 117 | 106 | 103 | 106 | 117 | 139 | 132 | 139 | 127 | |
Poultry Revenue — Reported growth YoY (%)(%) | 2.0% | 11.0% | 11.0% | 0.0% | -24.0% | -22.0% | -24.0% | -8.0% | 9.0% | 1.0% | 0.0% | 10.0% | |
Poultry Revenue — Foreign exchange impact YoY (%)(%) | -1.0% | 1.0% | 3.0% | 1.0% | 1.0% | -1.0% | -4.0% | -4.0% | -7.0% | -6.0% | -6.0% | -3.0% | |
Poultry Revenue — Operational (constant-currency) growth YoY (%)(%) | 3.0% | 10.0% | 8.0% | -1.0% | -25.0% | -21.0% | -20.0% | -4.0% | 16.0% | 7.0% | 6.0% | 13.0% | |
Poultry Revenue — Organic operational growth YoY (%)(%) | 3.0% | 10.0% | 8.0% | -1.0% | -25.0% | -21.0% | -20.0% | -4.0% | 16.0% | 7.0% | 6.0% | 13.0% | |
Fish (Aquaculture) Revenue ($M)($M)4 | 98 | 83 | 66 | 81 | 78 | 74 | 53 | 65 | 70 | 62 | 45 | 62 | |
Fish (Aquaculture) Revenue — Reported growth YoY (%)(%) | 23.0% | 2.0% | 20.0% | 25.0% | 11.0% | 19.0% | 18.0% | 5.0% | 23.0% | 19.0% | -8.0% | 2.0% | |
Fish (Aquaculture) Revenue — Foreign exchange impact YoY (%)(%) | 5.0% | 4.0% | 9.0% | 5.0% | 3.0% | 1.0% | -3.0% | 1.0% | -3.0% | -1.0% | -2.0% | -3.0% | |
Fish (Aquaculture) Revenue — Operational (constant-currency) growth YoY (%)(%) | 18.0% | -2.0% | 11.0% | 20.0% | 8.0% | 18.0% | 21.0% | 4.0% | 26.0% | 20.0% | -6.0% | 5.0% | |
Fish (Aquaculture) Revenue — Organic operational growth YoY (%)(%) | 18.0% | -2.0% | 11.0% | 20.0% | 8.0% | 18.0% | 21.0% | 4.0% | 26.0% | 20.0% | -6.0% | 5.0% | |
Sheep and Other Livestock Revenue ($M)($M)4 | 32 | 26 | 21 | 18 | 31 | 22 | 17 | 17 | 27 | 20 | 18 | 16 | |
Sheep and Other Livestock Revenue — Reported growth YoY (%)(%) | 10.0% | 4.0% | 5.0% | 6.0% | 15.0% | 10.0% | -6.0% | 6.0% | -7.0% | -23.0% | -38.0% | -16.0% | |
Sheep and Other Livestock Revenue — Foreign exchange impact YoY (%)(%) | 4.0% | 8.0% | 7.0% | -3.0% | -3.0% | 1.0% | -6.0% | -1.0% | -1.0% | -2.0% | -5.0% | 1.0% | |
Sheep and Other Livestock Revenue — Operational (constant-currency) growth YoY (%)(%) | 6.0% | -4.0% | -2.0% | 9.0% | 18.0% | 9.0% | 0.0% | 7.0% | -6.0% | -21.0% | -33.0% | -17.0% | |
Sheep and Other Livestock Revenue — Organic operational growth YoY (%)(%) | 6.0% | -4.0% | -2.0% | 9.0% | 18.0% | 9.0% | 0.0% | 7.0% | -6.0% | -21.0% | -33.0% | -17.0% | |
Total Livestock Revenue — Reported growth YoY (%)(%) | 7.0% | 12.0% | 15.0% | 4.0% | -4.0% | -8.0% | -10.0% | -3.0% | 6.0% | 3.0% | -5.0% | 5.0% | |
Total Livestock Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 2.0% | 5.0% | 1.0% | 1.0% | -2.0% | -5.0% | -4.0% | -5.0% | -6.0% | -4.0% | -1.0% | |
Total Livestock Revenue — Operational (constant-currency) growth YoY (%)(%) | 6.0% | 10.0% | 10.0% | 3.0% | -5.0% | -6.0% | -5.0% | 1.0% | 11.0% | 9.0% | -1.0% | 6.0% | |
Total Livestock Revenue — Divestitures impact YoY (%)(%) | -1.0% | -1.0% | -2.0% | -6.0% | -15.0% | -12.0% | -12.0% | ||||||
Total Livestock Revenue — Organic operational growth YoY (%)(%) | 7.0% | 11.0% | 12.0% | 9.0% | 10.0% | 6.0% | 7.0% | 1.0% | 11.0% | 9.0% | -1.0% | 6.0% | |
Product & Service Revenue by Veterinary Product Category ($M)($M) | 2,362 | 2,439 | 2,239 | 2,357 | 2,396 | 2,441 | 2,168 | 2,296 | 2,367 | 2,343 | 2,170 | 2,193 | |
Key Dermatology Portfolio (Apoquel, Apoquel Chewable & Cytopoint) — Global Revenue ($M)($M)3 | 396 | 395 | 347 | 469 | 460 | 387 | 417 | 449 | 414 | 360 | 375 | ||
Key Dermatology Portfolio — Global operational growth YoY (%)(%) | -16.0% | -16.0% | -11.0% | 3.0% | 11.0% | 10.0% | 11.0% | 16.0% | 25.0% | 7.0% | |||
Key Dermatology Portfolio — U.S. Revenue ($M)($M)1 | 266 | 251 | 215 | 272 | 306 | 307 | 249 | 270 | 303 | ||||
Key Dermatology Portfolio — U.S. operational growth YoY (%)(%) | -13.0% | -18.0% | -13.0% | 1.0% | 1.0% | 9.0% | 7.0% | 7.0% | 17.0% | ||||
Key Dermatology Portfolio — International Revenue ($M)($M)1 | 130 | 144 | 131 | 155 | 162 | 153 | 138 | 147 | 146 | 131 | 127 | 123 | |
Key Dermatology Portfolio — International operational growth YoY (%)(%) | -20.0% | -13.0% | -5.0% | 2.0% | 7.0% | 15.0% | 15.0% | 19.0% | 13.0% | 19.0% | 23.0% | 10.0% | |
Simparica Franchise (Simparica & Simparica Trio) — Global Revenue ($M)($M)3 | 358 | 442 | 385 | 333 | 356 | 448 | 367 | 324 | 333 | 384 | |||
Simparica Franchise — Global operational growth YoY (%)(%) | 1.0% | 0.0% | -1.0% | 3.0% | 7.0% | 17.0% | 19.0% | 21.0% | 27.0% | ||||
Simparica Franchise — U.S. Revenue ($M)($M)1 | 259 | 308 | 238 | 263 | 329 | 240 | 237 | ||||||
Simparica Franchise — U.S. operational growth YoY (%)(%) | -2.0% | -6.0% | -8.0% | 2.0% | 18.0% | 17.0% | |||||||
Simparica Franchise — International Revenue ($M)($M)2 | 99 | 134 | 147 | 90 | 93 | 119 | 106 | 84 | 75 | ||||
Simparica Franchise — International operational growth YoY (%)(%) | 10.0% | 19.0% | 14.0% | 6.0% | 22.0% | 16.0% | 23.0% | 32.0% | 28.0% | ||||
Simparica Trio — International Revenue ($M)($M) | 67 | 76 | 41 | 41 | 55 | 31 | 31 | ||||||
Osteoarthritis (OA) Pain mAbs Franchise (Librela/Lenivia & Solensia/Portela) — Global Revenue ($M)($M)3 | 137 | 147 | 140 | 137 | 138 | 147 | 150 | 149 | 131 | 124 | |||
OA Pain mAbs Franchise — Global operational growth YoY (%)(%) | 2.0% | -3.0% | -8.0% | -11.0% | -11.0% | 15.0% | 20.0% | ||||||
OA Pain mAbs Franchise — U.S. Revenue ($M)($M)3 | 51 | 51 | 55 | 53 | 62 | 65 | 71 | 73 | 71 | 57 | |||
OA Pain mAbs Franchise — U.S. operational growth YoY (%)(%) | -12.0% | -18.0% | -15.0% | -25.0% | -12.0% | 14.0% | 22.0% | ||||||
Canine OA Pain mAbs (Librela) — U.S. Revenue ($M)($M) | 34 | 37 | 36 | 41 | 45 | 47 | 53 | 55 | 53 | 40 | 44 | ||
Feline OA Pain mAbs (Solensia) — U.S. Revenue ($M)($M) | 17 | 18 | 17 | 17 | 17 | 18 | 18 | 18 | 14 | ||||
OA Pain mAbs Franchise — International Revenue ($M)($M)3 | 86 | 96 | 85 | 84 | 80 | 83 | 82 | 79 | 78 | 79 | 74 | ||
OA Pain mAbs Franchise — International operational growth YoY (%)(%) | 13.0% | 7.0% | -2.0% | 2.0% | -3.0% | 4.0% | 16.0% | 18.0% | 27.0% | 35.0% | 67.0% | ||
Canine OA Pain mAbs (Librela & Lenivia) — International Revenue ($M)($M) | 71 | 64 | 64 | 62 | 64 | 65 | 62 | 62 | 63 | 59 | 53 | ||
Feline OA Pain mAbs (Solensia & Portela) — International Revenue ($M)($M) | 24 | 21 | 21 | 18 | 19 | 18 | 17 | 16 | 16 | 15 | 13 | ||
Top 10 Selling Product Lines Share of Total Revenue (%)2 | |||||||||||||
Major Veterinary Product Categories (categories) | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 7 | |
Major Animal Species Covered (species) | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | |
Total Product & Service Revenue by Geographic Market ($M)($M)2 | 2,362 | 2,439 | 2,239 | 2,357 | 2,396 | 2,441 | 2,168 | 2,296 | 2,367 | 2,343 | 2,170 | 2,193 | |
United States Revenue ($M)($M)5 | 1,246 | 1,266 | 1,090 | 1,236 | 1,322 | 1,356 | 1,183 | 1,257 | 1,346 | 1,308 | 1,163 | 1,211 | |
United States Revenue — Reported growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | -2.0% | -2.0% | 4.0% | 2.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
United States Revenue — Foreign exchange impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
United States Revenue — Operational (constant-currency) growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | -2.0% | -2.0% | 4.0% | 2.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
United States Revenue — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | -2.0% | -5.0% | -3.0% | -4.0% | ||||||
United States Revenue — Organic operational growth YoY (%)(%) | -6.0% | -7.0% | -8.0% | 0.0% | 3.0% | 7.0% | 6.0% | 4.0% | 15.0% | 12.0% | 16.0% | 9.0% | |
Total International Markets Revenue ($M)($M)17 | 1,116 | 1,173 | 1,149 | 1,121 | 1,055 | 1,070 | 1,008 | 1,039 | 1,021 | 1,035 | 1,007 | 982 | |
Brazil ($M)($M)3 | 114 | 103 | 90 | 112 | 100 | 93 | 88 | 113 | 101 | 99 | 101 | 117 | |
Brazil — Reported growth YoY (%)(%) | 9.0% | 11.0% | 11.0% | -1.0% | -1.0% | -6.0% | -13.0% | -3.0% | 0.0% | 9.0% | 20.0% | 22.0% | |
Brazil — Foreign exchange impact YoY (%)(%) | 6.0% | 11.0% | 12.0% | 5.0% | 0.0% | -11.0% | -19.0% | -13.0% | -14.0% | -1.0% | 7.0% | 7.0% | |
Brazil — Organic operational growth YoY (%)(%) | 3.0% | 0.0% | -1.0% | -6.0% | -1.0% | 5.0% | 6.0% | 10.0% | 14.0% | 10.0% | 13.0% | 15.0% | |
Australia ($M)($M)3 | 104 | 94 | 89 | 84 | 87 | 83 | 75 | 80 | 83 | 83 | 73 | 75 | |
Australia — Reported growth YoY (%)(%) | 13.0% | 13.0% | 13.0% | 5.0% | 5.0% | 0.0% | 3.0% | 7.0% | -1.0% | 1.0% | -11.0% | 17.0% | |
Australia — Foreign exchange impact YoY (%)(%) | 9.0% | 11.0% | 11.0% | -3.0% | -1.0% | -4.0% | -5.0% | 5.0% | 0.0% | -1.0% | -4.0% | -2.0% | |
Australia — Organic operational growth YoY (%)(%) | 4.0% | 2.0% | 2.0% | 8.0% | 6.0% | 4.0% | 8.0% | 2.0% | -1.0% | 2.0% | -7.0% | 19.0% | |
United Kingdom ($M)($M)3 | 75 | 72 | 78 | 89 | 82 | 77 | 77 | 84 | 80 | 73 | 77 | 67.9 | |
United Kingdom — Reported growth YoY (%)(%) | -5.0% | -11.0% | 5.0% | 6.0% | 3.0% | 5.0% | 0.0% | 24.0% | 3.0% | 16.0% | 13.0% | 13.0% | |
United Kingdom — Foreign exchange impact YoY (%)(%) | 1.0% | -1.0% | 7.0% | 3.0% | 5.0% | 4.0% | -1.0% | 7.0% | 1.0% | 3.0% | 4.0% | 9.0% | |
United Kingdom — Organic operational growth YoY (%)(%) | -4.0% | -9.0% | -2.0% | 3.0% | -2.0% | 1.0% | 1.0% | 17.0% | 2.0% | 13.0% | 9.0% | 4.0% | |
Canada ($M)($M)3 | 70 | 72 | 73 | 80 | 70 | 73 | 67 | 75 | 66 | 75 | 61 | 71.1 | |
Canada — Reported growth YoY (%)(%) | -8.0% | 1.0% | 4.0% | 7.0% | 6.0% | -3.0% | 10.0% | 4.0% | 5.0% | 7.0% | 22.0% | 9.0% | |
Canada — Foreign exchange impact YoY (%)(%) | 0.0% | 0.0% | 4.0% | -2.0% | 0.0% | -3.0% | -7.0% | -1.0% | -3.0% | -1.0% | 1.0% | -2.0% | |
Canada — Organic operational growth YoY (%)(%) | 2.0% | 6.0% | 0.0% | 9.0% | 6.0% | 0.0% | 17.0% | 5.0% | 8.0% | 8.0% | 21.0% | 11.0% | |
Germany ($M)($M)3 | 51 | 69 | 59 | 65 | 62 | 58 | 51 | 59 | 57 | 58 | 51 | 54.1 | |
Germany — Reported growth YoY (%)(%) | -18.0% | 21.0% | 7.0% | 10.0% | 9.0% | 0.0% | 0.0% | 9.0% | 14.0% | 9.0% | 13.0% | 23.0% | |
Germany — Foreign exchange impact YoY (%)(%) | -2.0% | 2.0% | 11.0% | 6.0% | 8.0% | 1.0% | -4.0% | 2.0% | 1.0% | -1.0% | 1.0% | 8.0% | |
Germany — Organic operational growth YoY (%)(%) | -15.0% | 19.0% | -4.0% | 4.0% | 1.0% | -1.0% | 4.0% | 7.0% | 13.0% | 10.0% | 12.0% | 15.0% | |
China ($M)($M)3 | 61 | 62 | 63 | 50 | 45 | 72 | 60 | 65 | 61 | 68 | 76 | 64.7 | |
China — Reported growth YoY (%)(%) | 20.0% | -7.0% | 15.0% | -23.0% | -26.0% | 6.0% | -21.0% | 0.0% | -12.0% | -19.0% | -25.0% | -29.0% | |
China — Foreign exchange impact YoY (%)(%) | 6.0% | 7.0% | 5.0% | 0.0% | 0.0% | 0.0% | -1.0% | 1.0% | 0.0% | -3.0% | -3.0% | -1.0% | |
China — Organic operational growth YoY (%)(%) | 14.0% | -14.0% | 10.0% | -23.0% | -26.0% | 6.0% | -20.0% | -1.0% | -12.0% | -16.0% | -22.0% | -28.0% | |
France ($M)($M)3 | 37 | 40 | 37 | 52 | 40 | 33 | 40 | 45 | 36 | 34 | 41 | 40.5 | |
France — Reported growth YoY (%)(%) | 6.0% | -5.0% | -5.0% | 16.0% | 11.0% | -3.0% | -2.0% | 13.0% | 6.0% | 0.0% | 21.0% | 15.0% | |
France — Foreign exchange impact YoY (%)(%) | -3.0% | 3.0% | 9.0% | 8.0% | 6.0% | 3.0% | -4.0% | 3.0% | 2.0% | -2.0% | 1.0% | 8.0% | |
France — Organic operational growth YoY (%)(%) | 10.0% | -8.0% | -14.0% | 8.0% | 5.0% | -6.0% | 2.0% | 10.0% | 4.0% | 2.0% | 20.0% | 7.0% | |
Mexico ($M)($M)3 | 49 | 47 | 48 | 44 | 41 | 38 | 37 | 40 | 39 | 46 | 44 | 43.3 | |
Mexico — Reported growth YoY (%)(%) | 17.0% | 21.0% | 37.0% | 10.0% | 5.0% | -17.0% | -16.0% | -7.0% | -7.0% | 21.0% | 13.0% | 22.0% | |
Mexico — Foreign exchange impact YoY (%)(%) | 10.0% | 15.0% | 17.0% | 6.0% | 0.0% | -17.0% | -15.0% | -11.0% | -8.0% | 11.0% | 10.0% | 14.0% | |
Mexico — Organic operational growth YoY (%)(%) | 7.0% | 6.0% | 20.0% | 4.0% | 5.0% | 0.0% | -1.0% | 4.0% | 1.0% | 10.0% | 3.0% | 8.0% | |
Spain ($M)($M)3 | 37 | 43 | 40 | 37 | 38 | 37 | 33 | 30 | 35 | 33 | 32 | 27.3 | |
Spain — Reported growth YoY (%)(%) | 3.0% | 8.0% | 38.0% | 23.0% | 9.0% | 12.0% | 3.0% | 7.0% | 17.0% | 6.0% | -3.0% | 28.0% | |
Spain — Foreign exchange impact YoY (%)(%) | -2.0% | 2.0% | 16.0% | 8.0% | 6.0% | 4.0% | -4.0% | -1.0% | 3.0% | -2.0% | 1.0% | 9.0% | |
Spain — Organic operational growth YoY (%)(%) | 7.0% | 7.0% | 22.0% | 15.0% | 3.0% | 8.0% | 7.0% | 8.0% | 14.0% | 8.0% | -4.0% | 19.0% | |
Italy ($M)($M)3 | 30 | 40 | 39 | 35 | 35 | 38 | 29 | 34 | 31 | 36 | 28 | 33.9 | |
Italy — Reported growth YoY (%)(%) | -12.0% | 8.0% | 30.0% | 3.0% | 13.0% | 6.0% | 4.0% | 0.0% | 19.0% | 3.0% | 8.0% | 32.0% | |
Italy — Foreign exchange impact YoY (%)(%) | -2.0% | 1.0% | 16.0% | 7.0% | 7.0% | 4.0% | -5.0% | 2.0% | -3.0% | 1.0% | 2.0% | 9.0% | |
Italy — Organic operational growth YoY (%)(%) | -10.0% | 7.0% | 14.0% | -4.0% | 6.0% | 2.0% | 9.0% | -2.0% | 22.0% | 2.0% | 6.0% | 23.0% | |
Chile ($M)($M)3 | 34 | 34 | 38 | 40 | 29 | 36 | 34 | 30 | 31 | 31 | 31 | 31.4 | |
Chile — Reported growth YoY (%)(%) | 3.0% | 0.0% | 9.0% | 33.0% | -6.0% | 16.0% | 10.0% | -3.0% | 0.0% | -21.0% | -21.0% | -10.0% | |
Chile — Foreign exchange impact YoY (%)(%) | -2.0% | 0.0% | 6.0% | 3.0% | -2.0% | -3.0% | -1.0% | -2.0% | -6.0% | -4.0% | -4.0% | 1.0% | |
Chile — Organic operational growth YoY (%)(%) | 5.0% | 0.0% | 3.0% | 30.0% | -4.0% | 19.0% | 11.0% | -1.0% | 6.0% | -17.0% | -17.0% | -11.0% | |
Japan ($M)($M)3 | 26 | 41 | 35 | 39 | 34 | 45 | 36 | 38 | 33 | 39 | 37 | 38 | |
Japan — Reported growth YoY (%)(%) | -24.0% | -5.0% | 9.0% | 3.0% | 3.0% | 15.0% | -3.0% | 0.0% | -3.0% | -17.0% | -5.0% | 5.0% | |
Japan — Foreign exchange impact YoY (%)(%) | -6.0% | -11.0% | -4.0% | -1.0% | 5.0% | 5.0% | -5.0% | 1.0% | -6.0% | -13.0% | -9.0% | -4.0% | |
Japan — Organic operational growth YoY (%)(%) | -18.0% | 6.0% | 13.0% | 4.0% | -2.0% | 10.0% | 2.0% | -1.0% | 3.0% | -4.0% | 4.0% | 9.0% | |
Other Developed Markets ($M)($M)3 | 183 | 187 | 169 | 182 | 164 | 162 | 133 | 151 | 148 | 138 | 127 | 138 | |
Other Developed Markets — Reported growth YoY (%)(%) | 11.0% | 7.0% | 27.0% | 21.0% | 11.0% | 17.0% | 5.0% | 9.0% | 17.0% | 10.0% | 4.0% | 21.0% | |
Other Developed Markets — Foreign exchange impact YoY (%)(%) | 1.0% | 3.0% | 11.0% | 6.0% | 6.0% | 2.0% | -6.0% | 1.0% | -1.0% | -2.0% | 0.0% | 4.0% | |
Other Developed Markets — Organic operational growth YoY (%)(%) | 10.0% | 4.0% | 16.0% | 15.0% | 5.0% | 15.0% | 11.0% | 8.0% | 18.0% | 12.0% | 4.0% | 17.0% | |
Other Emerging Markets ($M)($M)3 | 245 | 269 | 291 | 212 | 228 | 225 | 248 | 195 | 220 | 222 | 228 | 179 | |
Other Emerging Markets — Reported growth YoY (%)(%) | 7.0% | 21.0% | 22.0% | 9.0% | 4.0% | 1.0% | 9.0% | 9.0% | 18.0% | 9.0% | 6.0% | 1.0% | |
Other Emerging Markets — Foreign exchange impact YoY (%)(%) | -2.0% | 1.0% | 3.0% | 0.0% | 0.0% | -1.0% | -8.0% | -17.0% | -19.0% | -25.0% | -25.0% | -13.0% | |
Other Emerging Markets — Organic operational growth YoY (%)(%) | 10.0% | 21.0% | 19.0% | 9.0% | 4.0% | 2.0% | 17.0% | 26.0% | 37.0% | 34.0% | 31.0% | 14.0% | |
Total International Markets Revenue — Reported growth YoY (%)(%) | 4.0% | 8.0% | 17.0% | 8.0% | 3.0% | 3.0% | 0.0% | 6.0% | 7.0% | 4.0% | 3.0% | 9.0% | |
Total International Markets Revenue — Foreign exchange impact YoY (%)(%) | 1.0% | 3.0% | 8.0% | 3.0% | 2.0% | -2.0% | -7.0% | -4.0% | -6.0% | -6.0% | -5.0% | 1.0% | |
Total International Markets Revenue — Organic operational growth YoY (%)(%) | 4.0% | 6.0% | 9.0% | 5.0% | 1.0% | 5.0% | 7.0% | 10.0% | 13.0% | 10.0% | 8.0% | 8.0% | |
Property, Plant and Equipment, Net by Geographic Region ($M)($M)1 | 3,782 | 3,756 | 3,719 | 3,693 | 3,600 | 3,537 | 3,441 | 3,391 | 3,298 | 3,200 | 3,251 | 3,204 | |
Countries Where Zoetis Products Are Marketed (countries) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
Total Reportable Operating Segments Earnings ($M)($M)6 | 1,430 | 1,498 | 1,336 | 1,404 | 1,455 | 1,513 | 1,330 | 1,342 | 1,431 | 1,390 | 1,291 | 1,260 | |
Total Reportable Segments Earnings — Reported growth YoY (%)(%) | -2.0% | -2.0% | 2.0% | 5.0% | 2.0% | 9.0% | 3.0% | 7.0% | 16.0% | 11.0% | 12.0% | 6.0% | |
Total Reportable Segments Earnings — Foreign exchange impact YoY (%)(%) | 1.0% | 1.0% | 2.0% | 2.0% | 1.0% | 2.0% | -2.0% | -1.0% | -2.0% | -4.0% | -4.0% | 0.0% | |
Total Reportable Segments Earnings — Operational growth YoY (%)(%) | -3.0% | -3.0% | 0.0% | 3.0% | 1.0% | 7.0% | 5.0% | 8.0% | 18.0% | 15.0% | 16.0% | 6.0% | |
Total Reportable Segments Depreciation & Amortization ($M)($M) | 50 | 49 | 49 | 49 | 50 | 48 | 46 | 43 | 45 | 46 | 47 | 47 | |
U.S. Operating Segment Earnings ($M)($M)7 | 830 | 837 | 697 | 830 | 899 | 930 | 779 | 819 | 889 | 872 | 756 | 766 | |
U.S. Segment Earnings — Reported growth YoY (%)(%) | -8.0% | -10.0% | -11.0% | 1.0% | 1.0% | 7.0% | 3.0% | 7.0% | 19.0% | 18.0% | 23.0% | 6.0% | |
U.S. Segment Earnings — Operational growth YoY (%)(%) | -8.0% | -10.0% | -11.0% | 1.0% | 1.0% | 7.0% | 3.0% | 7.0% | 19.0% | 18.0% | 23.0% | 6.0% | |
U.S. Segment Revenue ($M)($M) | 1,246 | 1,266 | 1,090 | 1,236 | 1,322 | 1,356 | 1,183 | 1,257 | 1,346 | 1,308 | 1,163 | 1,211 | |
U.S. Segment Cost of Sales ($M)($M)1 | 222 | 214 | 194 | 213 | 222 | 208 | 199 | 229 | 258 | 232 | 217 | 255 | |
U.S. Cost of Sales — Reported growth YoY (%)(%) | 0.0% | 3.0% | -3.0% | -7.0% | -14.0% | -10.0% | -8.0% | -10.0% | 13.0% | 8.0% | 7.0% | 18.0% | |
U.S. Segment Gross Profit ($M)($M)2 | 1,024 | 1,052 | 896 | 1,023 | 1,100 | 1,148 | 984 | 1,028 | 1,088 | 1,076 | 946 | 956 | |
U.S. Gross Profit — Reported growth YoY (%)(%) | -7.0% | -8.0% | -9.0% | 0.0% | 1.0% | 7.0% | 4.0% | 8.0% | 15.0% | 13.0% | 18.0% | 7.0% | |
U.S. Segment Gross Margin (%)(%) | 82.2% | 83.1% | 82.2% | 82.8% | 83.2% | 84.7% | 83.2% | 81.8% | 80.8% | 82.3% | 81.3% | 78.9% | |
U.S. Segment Operating Expenses ($M)($M)1 | 194 | 215 | 199 | 193 | 201 | 218 | 205 | 212 | 199 | 204 | 190 | 184 | |
U.S. Operating Expenses — Reported growth YoY (%)(%) | -3.0% | -1.0% | -3.0% | -9.0% | 1.0% | 7.0% | 8.0% | 15.0% | -1.0% | -4.0% | 1.0% | -2.0% | |
U.S. Segment Depreciation & Amortization ($M)($M) | 24 | 24 | 23 | 23 | 25 | 22 | 23 | 20 | 20 | 21 | 24 | 22 | |
International Operating Segment Earnings ($M)($M)8 | 600 | 661 | 639 | 574 | 556 | 583 | 551 | 523 | 542 | 518 | 535 | 494 | |
International Segment Earnings — Reported growth YoY (%)(%) | 7.0% | 12.0% | 21.0% | 10.0% | 3.0% | 13.0% | 3.0% | 6.0% | 10.0% | 1.0% | 0.0% | 5.0% | |
International Segment Earnings — Foreign exchange impact YoY (%)(%) | 2.0% | 4.0% | 6.0% | 4.0% | 3.0% | 5.0% | -4.0% | -4.0% | -5.0% | -10.0% | -9.0% | 0.0% | |
International Segment Earnings — Operational growth YoY (%)(%) | 5.0% | 8.0% | 15.0% | 6.0% | 0.0% | 8.0% | 7.0% | 10.0% | 15.0% | 11.0% | 9.0% | 5.0% | |
International Segment Revenue ($M)($M) | 1,116 | 1,173 | 1,149 | 1,121 | 1,055 | 1,070 | 1,008 | 1,039 | 1,021 | 1,035 | 1,007 | 982 | |
International Segment Cost of Sales ($M)($M)2 | 347 | 340 | 334 | 365 | 331 | 314 | 302 | 336 | 321 | 342 | 313 | 322 | |
International Cost of Sales — Reported growth YoY (%)(%) | 1.0% | 6.0% | 13.0% | 9.0% | 3.0% | -8.0% | -4.0% | 4.0% | 5.0% | 9.0% | 8.0% | 18.0% | |
International Cost of Sales — Operational growth YoY (%)(%) | 1.0% | 2.0% | 3.0% | 8.0% | 2.0% | 1.0% | 10.0% | 7.0% | 13.0% | 9.0% | 7.0% | 17.0% | |
International Segment Gross Profit ($M)($M)3 | 769 | 833 | 815 | 756 | 724 | 756 | 706 | 703 | 700 | 693 | 694 | 660 | |
International Gross Profit — Reported growth YoY (%)(%) | 5.0% | 9.0% | 18.0% | 8.0% | 3.0% | 9.0% | 2.0% | 7.0% | 8.0% | 2.0% | 1.0% | 5.0% | |
International Gross Profit — Operational growth YoY (%)(%) | 3.0% | 6.0% | 11.0% | 4.0% | 1.0% | 7.0% | 6.0% | 11.0% | 13.0% | 11.0% | 8.0% | 5.0% | |
International Segment Gross Margin (%)(%) | 68.9% | 71.0% | 70.9% | 67.4% | 68.6% | 70.7% | 70.0% | 67.7% | 68.6% | 67.0% | 68.9% | 67.2% | |
International Segment Operating Expenses ($M)($M)2 | 169 | 172 | 175 | 183 | 167 | 173 | 154 | 180 | 157 | 175 | 159 | 165 | |
International Operating Expenses — Reported growth YoY (%)(%) | 0.0% | 1.0% | 7.0% | 2.0% | 6.0% | -1.0% | -3.0% | 9.0% | 1.0% | 5.0% | 5.0% | 6.0% | |
International Operating Expenses — Operational growth YoY (%)(%) | -1.0% | -2.0% | 0.0% | -1.0% | 3.0% | 2.0% | 4.0% | 13.0% | 7.0% | 9.0% | 8.0% | 5.0% | |
International Segment Depreciation & Amortization ($M)($M) | 26 | 25 | 26 | 26 | 25 | 26 | 23 | 23 | 25 | 25 | 23 | 25 | |
Consolidated Income Before Provision for Taxes on Income ($M)($M)6 | 729 | 866 | 758 | 761 | 887 | 902 | 810 | 732 | 874 | 780 | 747 | 650 | |
Other Business Activities (Centralized R&D & Contract Manufacturing Net Loss) ($M)($M) | -134 | -135 | -141 | -159 | -140 | -134 | -129 | -151 | -137 | -142 | -132 | -142 | |
Reconciling Item — Corporate Expenses & Net Interest ($M)($M)1 | -303 | -315 | -315 | -342 | -306 | -321 | -271 | -320 | -306 | -299 | -288 | -320 | |
Corporate Depreciation & Amortization ($M)($M) | 23 | 26 | 25 | 26 | 26 | 29 | 29 | 32 | 31 | 33 | 32 | 33 | |
Reconciling Item — Purchase Accounting Adjustments ($M)($M)1 | -31 | -30 | -28 | -31 | -32 | -33 | -32 | -33 | -35 | -35 | -37 | -35 | |
Unallocated Purchase Accounting Intangible Amortization & Depreciation ($M)($M) | 31 | 31 | 31 | 31 | 32 | 33 | 32 | 34 | 35 | 35 | 37 | 37 | |
Reconciling Item — Acquisition and Divestiture-Related Costs ($M)($M)1 | -2 | -2 | -2 | -1 | 0 | -1 | 0 | -6 | -7 | -5 | 0 | -1 | |
Acquisition & Divestiture-Related Depreciation & Amortization ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Reconciling Item — Certain Significant Items ($M)($M)1 | -133 | -81 | -27 | -22 | -7 | -47 | -6 | -2 | -1 | -70 | -6 | -12 | |
Certain Significant Items Depreciation & Amortization ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Reconciling Item — Other Unallocated Global Manufacturing & Supply Overhead ($M)($M)1 | -98 | -69 | -65 | -88 | -83 | -75 | -82 | -98 | -71 | -59 | -81 | -100 | |
Other Unallocated Manufacturing Depreciation & Amortization ($M)($M) | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | |
Non-GAAP Adjusted Net Income Attributable to Zoetis ($M)($M)13 | 720 | 781 | 646 | 648 | 754 | 791 | 633 | 632 | 716 | 711 | 634 | 569 | |
Adjusted Net Income — Reported growth YoY (%)(%) | -5.0% | -1.0% | 2.0% | 3.0% | 5.0% | 10.0% | 4.0% | 11.0% | 14.0% | 9.0% | 4.0% | 6.0% | |
Adjusted Net Income — Foreign exchange impact YoY (%)(%) | 2.0% | 1.0% | 1.0% | 1.0% | 0.0% | 3.0% | 2.0% | 2.0% | -1.0% | -9.0% | -11.0% | 0.0% | |
Adjusted Net Income — Operational growth YoY (%)(%) | -7.0% | -2.0% | 1.0% | 2.0% | 5.0% | 7.0% | 2.0% | 9.0% | 15.0% | 18.0% | 15.0% | 6.0% | |
Adjusted Net Income — Divestitures impact YoY (%)(%) | 0.0% | 0.0% | 0.0% | -2.0% | -4.0% | -3.0% | -4.0% | ||||||
Adjusted Net Income — Organic operational growth YoY (%)(%) | -7.0% | -2.0% | 1.0% | 4.0% | 9.0% | 10.0% | 6.0% | 9.0% | 15.0% | 18.0% | 15.0% | 6.0% | |
Non-GAAP Adjusted Diluted Earnings per Common Share ($/sh)($) | 1.75 | 1.87 | 1.53 | 1.48 | 1.70 | 1.78 | 1.41 | 1.40 | 1.58 | 1.56 | 1.38 | 1.24 | |
Non-GAAP Adjusted Income Before Provision for Taxes ($M)($M) | 895 | 979 | 815 | 815 | 926 | 994 | 811 | 773 | 917 | 890 | 790 | 698 | |
Non-GAAP Adjusted Provision for Taxes on Income ($M)($M)1 | 175 | 198 | 169 | 167 | 172 | 203 | 178 | 141 | 191 | 179 | 156 | 131 | |
Effective Tax Rate on Adjusted Pre-Tax Income (%)(%) | 19.6% | 20.2% | 20.7% | 18.6% | 20.3% | 21.9% | 20.8% | 20.1% | |||||
Non-GAAP Adjusted Gross Profit ($M)($M)2 | 1,697 | 1,799 | 1,624 | 1,679 | 1,727 | 1,813 | 1,581 | 1,611 | 1,689 | 1,694 | 1,548 | 1,486 | |
Non-GAAP Adjusted Cost of Sales ($M)($M) | 694 | 669 | 638 | 708 | 695 | 661 | 617 | 706 | 699 | 667 | 642 | 727 | |
Non-GAAP Adjusted Cost of Sales (% of Revenue)(%) | 29.0% | 27.1% | 28.2% | 29.7% | 28.4% | 26.3% | 27.9% | 30.5% | 29.3% | 28.3% | 29.3% | 32.9% | |
Non-GAAP Adjusted SG&A Expenses ($M)($M)2 | 571 | 586 | 585 | 615 | 572 | 603 | 565 | 619 | 560 | 578 | 544 | 562 | |
Adjusted SG&A — Reported growth YoY (%)(%) | 0.0% | -3.0% | 4.0% | -1.0% | 2.0% | 5.0% | 2.0% | 10.0% | 7.0% | 5.0% | 9.0% | 11.0% | |
Adjusted SG&A — Operational growth YoY (%)(%) | 0.0% | -4.0% | 1.0% | -2.0% | 1.0% | 6.0% | 4.0% | 11.0% | 9.0% | 7.0% | 10.0% | 10.0% | |
Non-GAAP Adjusted R&D Expenses ($M)($M)2 | 174 | 173 | 179 | 199 | 174 | 165 | 162 | 186 | 166 | 171 | 161 | 174 | |
Adjusted R&D — Reported growth YoY (%)(%) | 0.0% | 5.0% | 10.0% | 7.0% | 2.0% | 0.0% | -2.0% | 7.0% | 10.0% | 17.0% | 13.0% | 18.0% | |
Adjusted R&D — Operational growth YoY (%)(%) | 0.0% | 4.0% | 9.0% | 5.0% | 1.0% | 1.0% | -2.0% | 7.0% | 10.0% | 17.0% | 13.0% | 17.0% | |
Non-GAAP Adjusted Amortization of Intangible Assets ($M)($M) | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 5 | 5 | |
Non-GAAP Adjusted Other (Income)/Deductions — Net ($M)($M) | -9 | -21 | -11 | -8 | -6 | -15 | -22 | -8 | -10 | -12 | |||
Non-GAAP Adjustment — Purchase Accounting Adjustments, Net of Tax ($M)($M)5 | 24 | 24 | 21 | 24 | 24 | 25 | 25 | 26 | 27 | 27 | 29 | 29 | |
Purchase Accounting Adjustments — Pre-Tax ($M)($M) | 31 | 30 | 28 | 31 | 32 | 33 | 32 | 33 | 35 | 35 | 37 | 35 | |
Acquisition and Divestiture-Related Costs — Net of Tax ($M)($M) | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 5 | 5 | 4 | 0 | 0 | |
Acquisition and Divestiture-Related Costs — Pre-Tax ($M)($M) | 2 | 2 | 2 | 1 | 0 | 1 | 0 | 6 | 7 | 5 | 0 | 1 | |
Certain Significant Items — Net of Tax ($M)($M) | 103 | 64 | 23 | 20 | 9 | 39 | 6 | 20 | 2 | 56 | 6 | 15 | |
Certain Significant Items — Pre-Tax ($M)($M) | 133 | 81 | 27 | 22 | 8 | 48 | 6 | 2 | 1 | 70 | 6 | 12 | |
Full-Year Financial Guidance — Revenue Range Low ($M)($M)11 | 9,220 | 9,120 | 9,680 | 9,825 | 9,400 | 9,450 | 9,425 | 9,225 | 9,200 | 9,100 | 9,050 | 9,075 | |
Full-Year Guidance — Revenue Range High ($M)($M) | 9,320 | 9,320 | 9,960 | 10,025 | 9,475 | 9,600 | 9,575 | 9,375 | 9,300 | 9,250 | 9,200 | 9,225 | |
Full-Year Guidance — Adjusted Net Income Range Low ($M)($M) | 2,600 | 2,570 | 2,870 | 2,975 | 2,800 | 2,825 | 2,775 | 2,700 | 2,670 | 2,640 | 2,620 | 2,650 | |
Full-Year Guidance — Adjusted Net Income Range High ($M)($M) | 2,640 | 2,620 | 2,950 | 3,025 | 2,840 | 2,875 | 2,825 | 2,750 | 2,695 | 2,690 | 2,670 | 2,700 | |
Full-Year Guidance — Adjusted Diluted EPS Range Low ($/sh)($) | 6.25 | 6.15 | 6.85 | 7 | 6.30 | 6.30 | 6.20 | 6 | 5.86 | 5.78 | 5.71 | 5.74 | |
Full-Year Guidance — Adjusted Diluted EPS Range High ($/sh)($) | 6.35 | 6.25 | 7 | 7.10 | 6.40 | 6.40 | 6.30 | 6.10 | 5.92 | 5.88 | 5.81 | 5.84 | |
Full-Year Guidance — Reported Diluted EPS Range Low ($/sh)($) | 5.50 | 5.55 | 6.35 | 6.65 | 5.90 | ||||||||
Full-Year Guidance — Reported Diluted EPS Range High ($/sh)($) | 5.60 | 5.65 | 6.50 | 6.75 | 6 | ||||||||
Full-Year Guidance — Adjusted SG&A Range Low ($M)($M) | 2,340 | 2,330 | 2,350 | 2,430 | 2,320 | 2,355 | 2,340 | 2,300 | 2,275 | 2,225 | 2,170 | 2,170 | |
Full-Year Guidance — Adjusted SG&A Range High ($M)($M) | 2,370 | 2,380 | 2,400 | 2,490 | 2,360 | 2,405 | 2,390 | 2,350 | 2,325 | 2,290 | 2,220 | 2,220 | |
Full-Year Guidance — Adjusted R&D Range Low ($M)($M) | 705 | 720 | 735 | 715 | 690 | 690 | 690 | 680 | 665 | 660 | 665 | 665 | |
Full-Year Guidance — Adjusted R&D Range High ($M)($M) | 715 | 730 | 745 | 725 | 700 | 700 | 700 | 690 | 675 | 670 | 675 | 675 | |
Accrued Sales Rebates and Revenue Deductions Liability [in Accrued Expenses] ($M)2 | |||||||||||||
Contract Liabilities (Deferred Revenue) ($M)($M) | 18 | 21 | 21 | 16 | 18 | 19 | 17 | 18 | 21 | 18 | 13 | 11 | |
Revenue Recognized from Beginning Contract Liability Balance ($M)($M) | 1 | 1 | 10 | -1 | 6 | 2 | 3 | 0 | 1 | 1 | 2 | 1 | |
Total Inventories, Net ($M)($M)4 | 2,536 | 2,574 | 2,550 | 2,464 | 2,465 | 2,439 | 2,365 | 2,306 | 2,416 | 2,452 | 2,651 | 2,564 | |
Finished Goods Inventory ($M)($M) | 1,170 | 1,147 | 1,081 | 1,094 | 1,076 | 1,041 | 983 | 996 | 1,049 | 1,050 | 1,120 | 1,147 | |
Work-in-Process Inventory ($M)($M) | 1,015 | 1,069 | 1,108 | 991 | 1,037 | 1,027 | 1,008 | 933 | 951 | 953 | 1,051 | 966 | |
Raw Materials and Supplies Inventory ($M)($M) | 351 | 358 | 361 | 379 | 352 | 371 | 374 | 377 | 416 | 449 | 480 | 451 | |
Inventory Write-Downs and Obsolescence Provision ($M)($M) | 31 | 13 | 13 | 16 | 20 | 16 | 19 | 26 | 29 | 25 | 17 | 33 | |
Property, Plant and Equipment, Net ($M)($M)1 | 3,782 | 3,756 | 3,719 | 3,693 | 3,600 | 3,537 | 3,441 | 3,391 | 3,298 | 3,200 | 3,251 | 3,204 | |
Accumulated Depreciation ($M)($M) | 3,136 | 3,066 | 3,002 | 2,935 | 2,872 | 2,796 | 2,697 | 2,635 | 2,657 | 2,590 | 2,673 | 2,594 | |
Total Goodwill ($M)($M)4 | 2,888 | 2,771 | 2,778 | 2,774 | 2,764 | 2,758 | 2,716 | 2,724 | 2,744 | 2,739 | 2,759 | 2,759 | |
U.S. Operating Segment Goodwill ($M)($M) | 1,622 | 1,515 | 1,515 | 1,515 | 1,515 | 1,515 | 1,515 | 1,515 | 1,515 | 1,515 | 1,532 | 1,532 | |
International Operating Segment Goodwill ($M)($M) | 1,266 | 1,256 | 1,263 | 1,259 | 1,249 | 1,243 | 1,201 | 1,209 | 1,229 | 1,224 | 1,227 | 1,227 | |
Goodwill, Gross ($M)($M) | 3,424 | 3,307 | 3,314 | 3,310 | 3,300 | 3,294 | 3,252 | 3,260 | 3,280 | 3,275 | 3,295 | 3,295 | |
Accumulated Goodwill Impairment Loss ($M)($M) | 536 | 536 | 536 | 536 | 536 | 536 | 536 | 536 | 536 | 536 | 536 | 536 | |
Identifiable Intangible Assets, Less Accumulated Amortization ($M)($M)3 | 850 | 918 | 959 | 998 | 1,040 | 1,075 | 1,082 | 1,127 | 1,186 | 1,226 | 1,295 | 1,338 | |
Finite-Lived Intangible Assets, Net ($M)($M)5 | 712 | 704 | 745 | 781 | 824 | 858 | 875 | 918 | 972 | 1,011 | 1,059 | 1,102 | |
Developed Technology Rights, Net ($M)($M) | 495 | 522 | 557 | 588 | 626 | 656 | 678 | 716 | 767 | 801 | 847 | 885 | |
Finite-Lived Trademarks and Trade Names, Net ($M)($M) | 104 | 106 | 109 | 111 | 114 | 116 | 119 | 121 | 125 | 128 | 134 | 137 | |
Other Finite-Lived Intangible Assets, Net ($M)($M) | 113 | 76 | 79 | 82 | 84 | 86 | 78 | 81 | 80 | 82 | 78 | 80 | |
Finite-Lived Intangible Assets, Gross ($M)($M) | 2,638 | 2,586 | 2,602 | 2,595 | 2,591 | 2,578 | 2,526 | 2,536 | 2,577 | 2,570 | 2,639 | 2,639 | |
Finite-Lived Intangible Assets — Accumulated Amortization ($M)($M) | 1,926 | 1,882 | 1,857 | 1,814 | 1,767 | 1,720 | 1,651 | 1,618 | 1,605 | 1,559 | 1,580 | 1,537 | |
Indefinite-Lived Intangible Assets (Excluding Goodwill) ($M)($M)3 | 138 | 214 | 214 | 217 | 216 | 217 | 207 | 209 | 214 | 215 | 236 | 236 | |
In-Process Research and Development (IPR&D) Assets ($M)($M) | 65 | 141 | 141 | 144 | 144 | 144 | 135 | 136 | 141 | 142 | 141 | 141 | |
Indefinite-Lived Trademarks and Trade Names ($M)($M) | 67 | 67 | 67 | 67 | 66 | 67 | 66 | 66 | 66 | 67 | 88 | 88 | |
Indefinite-Lived Product Rights ($M)($M) | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 6 | 7 | 7 | |
Amortization of Intangible Assets ($M)($M)1 | 39 | 38 | 39 | 38 | 39 | 40 | 40 | 42 | 42 | 42 | 44 | 44 | |
Intangible Asset Impairment Charges ($M)($M) | 78 | 0 | 0 | 0 | 5 | 4 | 0 | 11 | 18 | ||||
Operating Lease Right-of-Use (ROU) Assets ($M)($M)3 | 269 | 275 | 282 | 289 | 292 | 302 | 220 | 219 | 223 | 222 | 225 | 230 | |
Operating Lease Liabilities — Noncurrent ($M)($M) | 188 | 190 | 193 | 197 | 204 | 210 | 173 | 174 | 181 | 181 | 184 | 188 | |
Operating Cash Flows Used for Operating Leases ($M)($M) | 15 | 19 | 17 | 11 | 24 | 18 | 16 | 15 | 16 | 15 | 15 | 15 | |
ROU Assets Obtained in Exchange for New Operating Lease Liabilities ($M)($M) | 10 | 7 | 10 | 15 | 3 | 51 | 7 | 7 | 13 | 18 | 8 | -1 | |
Long-Term Debt, Net of Current Portion ($M)($M)6 | 8,299 | 9,048 | 9,045 | 9,042 | 7,069 | 5,231 | 5,227 | 5,220 | 6,574 | 6,563 | 6,562 | 6,564 | |
Current Portion of Long-Term Debt ($M)($M) | 750 | 0 | 0 | 1,350 | 1,350 | 1,350 | 0 | ||||||
Revolving Credit Facility Maximum Borrowing Capacity ($M)($M) | 46 | 46 | 47 | 51 | 1,750 | 53 | 51 | 50 | 56 | 55 | 60 | 56 | |
Long-Term Debt Maturities — Year 1 ($M)($M) | 750 | 750 | 750 | 0 | 0 | 0 | 0 | 1,350 | 1,350 | 1,350 | 1,350 | 0 | |
Long-Term Debt Maturities — Year 2 ($M)($M) | 1,350 | 1,350 | 1,350 | 750 | 750 | 750 | 750 | 0 | 0 | 0 | 0 | 1,350 | |
Long-Term Debt Maturities — Year 3 ($M)($M) | 2,000 | 2,000 | 2,000 | 1,350 | 1,350 | 500 | 500 | 750 | 750 | 750 | 750 | 0 | |
Long-Term Debt Maturities — Year 4 ($M)($M) | 750 | 750 | 750 | 2,000 | 0 | 0 | 0 | 500 | 500 | 500 | 500 | 750 | |
Cash Paid for Share Repurchases ($M)($M)8 | 500 | -345 | 1,535 | 2,060 | 394 | 338 | 443 | 553 | 433 | 533 | 339 | 235 | |
Common Stock Repurchased — Aggregate Value ($M)($M) | 505 | 558 | 612 | 2,080 | 381 | 341 | 447 | 558 | 427 | 538 | 342 | 238 | |
Common Stock Repurchased — Shares (M shares)(M) | 6.70 | 6.20 | 12.3 | 16.6 | 2.50 | 2.10 | 2.70 | 3.20 | 2.30 | 3.20 | 1.80 | 1.30 | |
Treasury Stock Carrying Value ($M)($M) | 12,349 | 11,845 | 11,288 | 10,685 | 8,606 | 8,226 | 7,888 | 7,445 | 6,889 | 6,464 | 5,928 | 5,597 | |
Common Stock Held in Treasury (M shares)(M) | 94.4 | 87.7 | 81.5 | 77.0 | 60.4 | 58.0 | 55.9 | 53.4 | 50.3 | 48.1 | 44.9 | 43.5 | |
Cash Dividends Declared ($M)($M) | -2 | 220 | 216 | 452 | 0 | 221 | 224 | 418 | 0 | 196 | 198 | 370 | |
Cash Dividends Paid ($M)($M) | 219 | 223 | 224 | 220 | 222 | 223 | 224 | 194 | 197 | 197 | 198 | 172 | |
Dividends Payable ($M)($M) | 0 | 221 | 224 | 232 | 0 | 222 | 224 | 224 | 0 | 197 | 198 | 198 | |
Stock-Based Compensation Expense ($M)($M)3 | 27 | 26 | 25 | 22 | 22 | 22 | 17 | 19 | 18 | 19 | 18 | 17 | |
SBC Grant Allocation — Restricted Stock Units (RSUs) & DSUs ($M)($M) | 19 | 19 | 16 | 14 | 14 | 13 | 11 | 11 | 10 | 11 | 10 | 10 | |
SBC Grant Allocation — Performance-Vesting Share Units (PSUs) ($M)($M) | 5 | 3 | 5 | 5 | 5 | 6 | 3 | 5 | 6 | 5 | 5 | 5 | |
SBC Grant Allocation — Stock Options ($M)($M) | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | |
Restructuring Accrual Reserve — Total Ending Balance ($M)($M)4 | 93 | 95 | 33 | 25 | 18 | 20 | 20 | 28 | 46 | 55 | 27 | 35 | |
Restructuring Reserve — Current Liability ($M)($M) | 91 | 93 | 31 | 23 | 16 | 18 | 18 | 26 | 44 | 53 | 25 | 26 | |
Restructuring Reserve — Noncurrent Liability ($M)($M) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 9 | |
Restructuring Charges and Certain Acquisition/Divestiture Costs ($M)($M) | 41 | 75 | 20 | 16 | 4 | -3 | -2 | 37 | 11 | 8 | |||
Restructuring Reserve Utilized / Cash Payments ($M)($M) | 32 | 13 | 12 | 5 | 6 | 7 | 8 | 15 | 7 | 9 | 12 | 7 | |
GAAP Effective Income Tax Rate (%)(%)2 | 1,890.0% | 2,020.0% | 2,070.0% | 1,860.0% | 2,040.0% | 2,210.0% | 2,080.0% | 2,000.0% | 1,980.0% | ||||
Deferred Tax Assets, Net of Valuation Allowance ($M)($M) | 608 | 617 | 591 | 636 | 587 | 617 | 530 | 540 | 409 | 366 | 232 | 206 | |
Gross Unrecognized Tax Benefits (UTB) ($M)($M) | 228 | 226 | 223 | 222 | 220 | 219 | 215 | 213 | 217 | 214 | 212 | 209 | |
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Income Statement — Revenue ($M)($M)14 | 2,391 | 2,468 | 2,262 | 2,373 | 2,422 | 2,474 | 2,198 | 2,317 | 2,388 | 2,361 | 2,190 | 2,213 | |
Cost of sales ($M)($M) | 698 | 673 | 641 | 687 | 697 | 664 | 618 | 707 | 701 | 668 | 643 | 728 | |
Selling, general and administrative expenses ($M)($M) | 582 | 592 | 588 | 608 | 582 | 614 | 574 | 625 | 565 | 581 | 547 | 565 | |
Research and development expenses ($M)($M) | 174 | 173 | 180 | 195 | 175 | 166 | 162 | 186 | 167 | 171 | 162 | 174 | |
Restructuring charges and certain acquisition-related costs ($M)($M) | 41 | 75 | 20 | 16 | 4 | -3 | -2 | 37 | 11 | 8 | |||
Interest expense, net of capitalized interest ($M)($M) | 62 | 61 | 62 | 57 | 58 | 53 | 54 | 51 | 57 | 59 | 58 | 59 | |
Other (income)/deductions — net ($M)($M) | -72 | 5 | 20 | 11 | 12 | -2 | 15 | 20 | 16 | -25 | 8 | 8 | |
Income before provision for taxes on income ($M)($M) | 729 | 866 | 758 | 789 | 886 | 912 | 773 | 732 | 874 | 780 | 747 | 650 | |
Provision for taxes on income ($M)($M) | 138 | 175 | 157 | 165 | 165 | 186 | 171 | 151 | 182 | 156 | 148 | 127 | |
Net income attributable to Zoetis Inc. ($M)($M) | 591 | 691 | 601 | 624 | 721 | 726 | 602 | 581 | 682 | 624 | 599 | 525 | |
Earnings per share — Basic ($/sh)($) | 1.44 | 1.65 | 1.42 | 1.63 | 1.63 | 1.34 | 1.51 | 1.37 | 1.31 | ||||
Earnings per share — Diluted ($/sh)($) | 1.44 | 1.65 | 1.42 | 1.63 | 1.63 | 1.34 | 1.50 | 1.37 | 1.31 | ||||
Weighted-average basic shares outstanding (M)(M) | 412 | 418 | 422 | 443 | 445 | 448 | 453 | 456 | 458 | ||||
Weighted-average diluted shares outstanding (M)(M) | 412 | 418 | 422 | 443 | 446 | 448 | 454 | 456 | 459 | ||||
Dividends declared per common share ($/sh)($) | 0 | 0.53 | 0.53 | 1.03 | 0 | 0.50 | 0.50 | 0.93 | 0 | 0.43 | 0.43 | 0.81 | |
Balance Sheet — Total assets ($M)($M)14 | 15,088 | 15,077 | 15,154 | 15,490 | 15,159 | 14,479 | 14,098 | 14,237 | 14,357 | 14,165 | 14,348 | 14,286 | |
Cash and cash equivalents ($M)($M) | 1,333 | 1,476 | 1,941 | 2,450 | 2,270 | 1,632 | 1,782 | 2,114 | 1,714 | 1,574 | 1,975 | 2,041 | |
Accounts receivable, less allowance for doubtful accounts ($M)($M) | 1,692 | 1,571 | 1,506 | 1,409 | 1,541 | 1,540 | 1,361 | 1,316 | 1,411 | 1,383 | 1,293 | 1,304 | |
Inventories ($M)($M) | 2,536 | 2,574 | 2,550 | 2,464 | 2,465 | 2,439 | 2,365 | 2,306 | 2,416 | 2,452 | 2,651 | 2,564 | |
Total current assets ($M)($M) | 6,293 | 6,356 | 6,474 | 6,773 | 6,583 | 5,923 | 5,877 | 5,986 | 6,282 | 6,202 | 6,359 | 6,343 | |
Property, plant and equipment, less accumulated depreciation ($M)($M) | 3,782 | 3,756 | 3,719 | 3,693 | 3,600 | 3,537 | 3,441 | 3,391 | 3,298 | 3,200 | 3,251 | 3,204 | |
Operating lease right-of-use assets ($M)($M) | 269 | 275 | 282 | 289 | 292 | 302 | 220 | 219 | 223 | 222 | 225 | 230 | |
Goodwill ($M)($M) | 2,888 | 2,771 | 2,778 | 2,774 | 2,764 | 2,758 | 2,716 | 2,724 | 2,744 | 2,739 | 2,759 | 2,759 | |
Identifiable intangible assets, less accumulated amortization ($M)($M) | 850 | 918 | 959 | 998 | 1,040 | 1,075 | 1,082 | 1,127 | 1,186 | 1,226 | 1,295 | 1,338 | |
Accounts payable ($M)($M) | 419 | 452 | 507 | 445 | 410 | 508 | 420 | 433 | 404 | 420 | 405 | 411 | |
Total current liabilities ($M)($M) | 2,682 | 2,061 | 2,053 | 2,173 | 1,807 | 3,366 | 3,385 | 3,412 | 1,702 | 1,797 | 1,909 | 1,889 | |
Long-term debt, net of discount and issuance costs ($M)($M) | 8,299 | 9,048 | 9,045 | 9,042 | 7,069 | 5,231 | 5,227 | 5,220 | 6,574 | 6,563 | 6,562 | 6,564 | |
Total liabilities ($M)($M) | 11,785 | 11,929 | 11,921 | 12,075 | 9,761 | 9,502 | 9,443 | 9,467 | 9,123 | 9,205 | 9,296 | 9,295 | |
Retained earnings ($M)($M) | 15,246 | 14,653 | 14,183 | 13,798 | 13,593 | 12,872 | 12,375 | 11,968 | 11,806 | 11,124 | 10,696 | 10,295 | |
Total Zoetis Inc. shareholders' equity ($M)($M) | 3,303 | 3,148 | 3,233 | 3,415 | 5,398 | 4,977 | 4,655 | 4,770 | 5,234 | 4,966 | 5,058 | 4,997 | |
Cash Flow Statement — Net cash provided by operating activities ($M)($M)5 | 824 | 655 | 401 | 848 | 936 | 605 | 515 | 905 | 951 | 502 | 595 | 897 | |
Depreciation and amortization ($M)($M) | 119 | 119 | 119 | 122 | 122 | 124 | 119 | 123 | 121 | 127 | 126 | 126 | |
Share-based compensation expense ($M)($M) | 27 | 26 | 25 | 22 | 22 | 22 | 17 | 19 | 18 | 19 | 18 | 17 | |
Capital expenditures ($M)($M) | 107 | 117 | 110 | 159 | 138 | 146 | 178 | 216 | 167 | 132 | 140 | 198 | |
Net cash used in investing activities ($M)($M) | -262 | -300 | -87 | -165 | -168 | -212 | -203 | 126 | -178 | -132 | -131 | -210 | |
Net cash used in financing activities ($M)($M) | -718 | -813 | -840 | -495 | -134 | -564 | -677 | -745 | -628 | -763 | -524 | -397 | |
28 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & 2026 Fiscal Year Alignment: Zoetis Inc. reports on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). Through FY2025, subsidiaries operating outside the United States closed their fiscal year on November 30; beginning in Q1 2026, Zoetis eliminated the one-month reporting lag so all U.S. and international operations report on a uniform December 31 fiscal calendar.
- Core operational & commercial KPIs (Groups 1–6) cover: (1) Segment & Segment × Species Revenue ($2,391M in Q3 2026 / $9,467M in FY25 across U.S. $1,246M [Companion Animal $980M, Livestock $266M], International $1,116M [Companion Animal $585M, Livestock $531M], and Contract Manufacturing & Human Health $29M) along with the full Reported, Foreign Exchange, Operational, Divestiture, and Organic Operational growth bridge and MD&A Price vs. Volume drivers; (2) Species Revenue Breakdown across Companion Animal ($1,565M in Q3 2026: Dogs & Cats $1,492M, Horses $73M) and Livestock ($797M in Q3 2026: Cattle $439M, Swine $120M, Poultry $108M, Fish $98M, Sheep & Other $32M), correcting the 2018–2025 Form 10-K XBRL preparer tag swap between DogsAndCatsMember and HorsesMember; (3) Veterinary Product Categories ($2,362M in Q3 2026: Parasiticides $564M, Vaccines $496M, Dermatology $419M, Anti-Infectives $286M, Pain & Sedation $247M, Other Pharmaceuticals $175M, Animal Health Diagnostics $125M, Other Non-Pharmaceuticals $50M, plus Medicated Feed Additives divested Oct 31, 2024), Blockbuster Franchises from earnings call transcripts (Key Dermatology $396M, Simparica Franchise $358M, OA Pain mAbs $137M in Q3 2026 across U.S. & International), and Top Product/Customer Concentration; (4) Geographic Revenue across the U.S. and 14 Key International Markets (Brazil $114M, Australia $104M, U.K. $75M, Canada $70M, China $61M, Germany $51M, Mexico $49M, France $37M, Spain $37M, Chile $34M, Italy $30M, Japan $26M, Other Developed $183M, Other Emerging $245M in Q3 2026); (5) Segment P&L & Margins (U.S. Gross Margin 82.2% and Segment Earnings $830M; International Gross Margin 68.9% and Segment Earnings $600M in Q3 2026) and Reconciling Items; and (6) Non-GAAP Adjusted P&L ($720M Adjusted Net Income / $1.75 Adjusted Diluted EPS in Q3 2026; $2,847M / $6.41 in FY25) and Full-Year 2026 Guidance evolution.
- Balance Sheet, Capital, Workforce & ESG KPIs (Groups 7–10) cover: (7) Gross-to-Net Sales Deductions ($395M accrued rebate liability and $260M AR allowance at FY25), Inventories by Manufacturing Stage ($2,383M net at Q3 2026: Finished Goods $1,123M, WIP $798M, Raw Materials $462M), PP&E by Asset Class ($3,365M net at Q3 2026; 21 internal manufacturing sites in FY25), Goodwill ($2,859M) & Intangibles ($1,093M net at Q3 2026), and Operating Leases; (8) Debt & 5-Year Maturity Schedule ($5,921M noncurrent long-term debt at Q3 2026), Share Repurchases ($1,967M in Q1–Q3 2026) & SBC by Award Type, Restructuring Reserves, Defined Benefit Pensions & Income Taxes; (9) Global Workforce (14,500 employees: 6,800 U.S., 7,700 International; 1,700 R&D colleagues; 3,900 sales colleagues; 87% engagement in FY25), CEO Pay Ratio (244:1 / $80,592 median employee in FY25), Form 11-K Zoetis Savings Plan ($2.11B net assets at FY25), Safety (0.31 TIR / 0.18 LTIR in FY25), Form SD 3TG Smelters, and Scope 1/2/3 GHG Emissions, Energy, Water & Waste; and (10) FRED Pharmaceutical & Livestock Benchmarks and Core Financial Statements from Postgres DB.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (21)
- Revenue by Operating Segment, Segment × Species & Growth Bridge (Volume, Price, FX & Divestitures) › Total Consolidated Revenue ($M) › MD&A Operational Revenue Change YoY ($M) › MD&A Revenue Driver — Price Growth / (Decline) Contribution (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Brazil ($M) › Brazil — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Australia ($M) › Australia — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › United Kingdom ($M) › United Kingdom — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Canada ($M) › Canada — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Germany ($M) › Germany — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › China ($M) › China — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › France ($M) › France — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Mexico ($M) › Mexico — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Spain ($M) › Spain — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Italy ($M) › Italy — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Chile ($M) › Chile — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Japan ($M) › Japan — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Other Developed Markets ($M) › Other Developed Markets — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Other Emerging Markets ($M) › Other Emerging Markets — Divestitures impact YoY (%)
- Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region › Total Product & Service Revenue by Geographic Market ($M) › Total International Markets Revenue ($M) › Total International Markets Revenue — Divestitures impact YoY (%)
- Commercial Reach — Countries Where Products Are Sold ('over 100 countries' — bounded disclosure in 10-K/8-K; exact XBRL count of ~45 direct-operation countries is included in Group 4)
- R&D Pipeline — Active Research and Development Programs ('over 300 programs' — bounded disclosure in Form 10-K Item 1)
- External Contract Manufacturing Network — Third-Party CMOs ('more than 90 third-party contract manufacturing organizations' — bounded disclosure in Form 10-K Item 1)
- Osteoarthritis Pain mAbs — Cumulative Doses & Treated Patients ('over 30 million doses of Librela and Solensia distributed globally' / 'over 1.2 million patients' — bounded cumulative callouts in earnings calls)
- Companion Animal Addressable Market Projections — Dermatology & Triple-Combination TAM ('$2.5B by 2028' / '$4.5B by 2028' — forward-looking multi-year industry TAM estimates from Q4 call)
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Revenue by Operating Segment, Segment × Species & Growth Bridge (Volume, Price, FX & Divestitures)
Revenue by Animal Species — Companion Animal (Dogs & Cats, Horses) & Livestock (Cattle, Swine, Poultry, Fish, Sheep)
Revenue by Veterinary Product Category, Blockbuster Franchises (Dermatology, Simparica, OA Pain mAbs) & Concentration
- Product & Service Revenue by Veterinary Product Category ($M) ($M)39 kỳ
- Key Dermatology Portfolio (Apoquel, Apoquel Chewable & Cytopoint) — Global Revenue ($M) ($M)11 kỳ
- Simparica Franchise (Simparica & Simparica Trio) — Global Revenue ($M) ($M)10 kỳ
- Osteoarthritis (OA) Pain mAbs Franchise (Librela/Lenivia & Solensia/Portela) — Global Revenue ($M) ($M)10 kỳ
- Top 10 Selling Product Lines Share of Total Revenue (%) (%)0 kỳ
Revenue by Geographic Country (U.S. & 14 International Markets) & Long-Lived Assets by Region
Operating Segment P&L (U.S. vs. International), Gross Margins, Centralized R&D & Corporate Reconciling Items
Non-GAAP Adjusted P&L, GAAP-to-Non-GAAP Reconciling Items & Full-Year Financial Guidance Evolution
Gross-to-Net Sales Deductions, Inventories by Manufacturing Stage, PP&E, Goodwill, Intangibles & Leases
- Accrued Sales Rebates and Revenue Deductions Liability [in Accrued Expenses] ($M) ($M)11 kỳ
- Total Inventories, Net ($M) ($M)47 kỳ
- Property, Plant and Equipment, Net ($M) ($M)47 kỳ
- Total Goodwill ($M) ($M)47 kỳ
- Identifiable Intangible Assets, Less Accumulated Amortization ($M) ($M)47 kỳ
- Operating Lease Right-of-Use (ROU) Assets ($M) ($M)33 kỳ
Debt & 5-Year Maturity Schedule, Share Repurchases, Restructuring Reserve, Benefit Plans & Income Taxes
- Long-Term Debt, Net of Current Portion ($M) ($M)47 kỳ
- Cash Paid for Share Repurchases ($M) ($M)47 kỳ
- Restructuring Accrual Reserve — Total Ending Balance ($M) ($M)47 kỳ
- International Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) [year-end] ($M) ($M)11 kỳ
- GAAP Effective Income Tax Rate (%) (%)36 kỳ
Global Workforce, R&D & Sales Colleagues, 401(k) Savings Plan, CEO Pay Ratio & Sustainability (ESG)
- Global Workforce — Total Worldwide Employees (colleagues)11 kỳ
- CEO to Median Employee Pay Ratio (x:1) (×)7 kỳ
- Zoetis Savings Plan (Form 11-K 401(k) Plan) — Net Assets Available for Benefits ($K)9 kỳ
- Occupational Health & Safety — Total Injury Rate (TIR, injuries per 100 colleagues) (×)4 kỳ
- Climate — Total Scope 1 & 2 Market-Based GHG Emissions (tCO2e)6 kỳ
- Energy — Total Global Energy Consumption (GJ)6 kỳ
Industry & Livestock Benchmarks (FRED) & Core Financial Statements (DB)
- PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)129 kỳ
- PPI: Farm Products — Livestock & Agriculture Producer Benchmark (Index 1982=100)129 kỳ
- U.S. Retail Sales: Pharmacies and Drug Stores — Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B)43 kỳ
- Income Statement — Revenue ($M) ($M)59 kỳ
- Balance Sheet — Total assets ($M) ($M)56 kỳ
- Cash Flow Statement — Net cash provided by operating activities ($M) ($M)59 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Zoetis
See a number that looks wrong?